B-cell acute lymphoblastic leukemia after lenalidomide maintenance therapy; a deleterious adverse event that needs further investigation. Report of three cases and review of the literature

References

• Usmani SZ, Hoering A, Cavo M, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma—an IMWG research project. Blood Cancer J. 2018;8(12):1-7 doi:10.1038/s41408-018-0155-7
   PubMedGoogle Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):309–322. doi:10.1016/j.annonc.2020.11.014
   PubMed Web of Science ®Google Scholar
• Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020;38(17):1928–1937. doi:10.1200/JCO.19.02515
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770–1781. doi:10.1056/NEJMoa1114083
   PubMed Web of Science ®Google Scholar
• Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782–1791. doi:10.1056/NEJMoa1114138
   PubMed Web of Science ®Google Scholar
• Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012;366(19):1759–1769. doi:10.1056/NEJMoa1112704
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Kang J, Havens CG, et al. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors ikaros and aiolos via modulation of the E3 ubiquitin ligase complex CRL4 (CRBN.). Br J Haematol. 2014;164(6):811–821. Mar doi:10.1111/bjh.12708
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35(29):3279–3289. doi:10.1200/JCO.2017.72.6679
   PubMed Web of Science ®Google Scholar
• Palumbo A, Bringhen S, Kumar SK, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15(3):333–342. doi:10.1016/S1470-2045(13)70609-0
   PubMed Web of Science ®Google Scholar
• Dores GM, Coté TR, Travis LB. New malignancies following hodgkin lymphoma, Non-Hodgkin lymphoma, and myeloma. In: Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker MA, Fraumeni JF Jr. (eds). New malignancies among cancer survivors: SEER cancer registries, 1973-2000. National cancer institute, NIH publ. No. 05-5302. Bethesda, MD, 2006. Chapter 16. Available from: https://seer.cancer.gov/archive/publications/mpmono/index.html.
   Google Scholar
• Gonzalez MM, Kidd L, Quesada J, et al. Acute myelofibrosis and acute lymphoblastic leukemia in an elderly patient with previously treated multiple myeloma. Ann Clin Lab Sci. 2013;43(2):176–180.
   PubMed Web of Science ®Google Scholar
• García-Muñoz R, Robles-De-Castro D, Muñoz-Rodríguez A, et al. Acute lymphoblastic leukemia developing during maintenance therapy with lenalidomide in a patient with multiple myeloma. Leuk Lymphoma. 2013;54(12):2753–2755. doi:10.3109/10428194.2013.786072
   PubMed Web of Science ®Google Scholar
• Tan M, Fong R, Lo M, et al. Lenalidomide and secondary acute lymphoblastic leukemia: a case series. Hematol Oncol. 2017;35(1):130–134. doi:10.1002/hon.2248
   PubMed Web of Science ®Google Scholar
• Sinit RB, Hwang DG, Vishnu P, et al. B-cell acute lymphoblastic leukemia in an elderly man with plasma cell myeloma and long-term exposure to thalidomide and lenalidomide: a case report and literature review. BMC Cancer. 2019;19(1):1–9. doi:10.1186/s12885-019-6286-9
   PubMed Web of Science ®Google Scholar
• Germans SK, Kulak O, Koduru P, et al. Lenalidomide-Associated secondary B-Lymphoblastic leukemia/lymphoma—a unique entity. Am J Clin Pathol. 2020;154(6):816–827. doi:10.1093/ajcp/aqaa109
   PubMed Web of Science ®Google Scholar
• Tashakori M, Khoury JD. B acute lymphoblastic leukemia arising during maintenance therapy for multiple myeloma. Blood. 2020; Dec136(23):2720. doi:10.1182/blood.2020009141
   PubMed Web of Science ®Google Scholar
• Khan SR, Tariq M, Fayyaz SM, et al. Lenalidomide induced secondary acute lymphoblastic leukemia in a multiple myeloma patient: a case report. Leuk Res Rep. 2022;17:100315. doi:10.1016/j.lrr.2022.100315
   PubMedGoogle Scholar
• Aldoss I, Capelletti M, Park J, et al. Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma. Leukemia. 2019;33(1):266–270. doi:10.1038/s41375-018-0213-y
   PubMed Web of Science ®Google Scholar
• Parrondo RD, Rahman ZA, Heckman MG, et al. Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. Blood Cancer J. 2022;12(6):87. doi:10.1038/s41408-022-00680-y
   PubMed Web of Science ®Google Scholar
• Ribera JM, Garcia O, Oriol A, et al. Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group. Leuk Res. 2016;41:12–20. doi:10.1016/j.leukres.2015.11.012
   PubMed Web of Science ®Google Scholar
• Molina O, Bataller A, Thampi N, et al. Near-haploidy and low-hypodiploidy in b-cell acute lymphoblastic leukemia: when less is too much. Cancers. 2021;14(1):32. doi:10.3390/cancers14010032
   PubMed Web of Science ®Google Scholar
• Aldoss I, Stiller T, Tsai NC, et al. Therapy-related acute lymphoblastic leukemia has distinct clinical and ctyogenetic features compared to de novo acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients. Haematologica. 2018;103(10):1662–1668. doi:10.3324/haematol.2018.193599
   PubMed Web of Science ®Google Scholar
• Aldoss I, Forman SJ, Pullarkat V. Acute lymphoblastic leukemia in the older adult. J Oncol Pract. 2019; 15(2):67–75. doi:10.1200/JOP.18.00271
   PubMed Web of Science ®Google Scholar
• Barnell EK, Skidmore ZL, Newcomer KF, et al. Distinct clonal identities of B-ALLs arising after lenolidomide therapy for multiple myeloma. Blood Adv. 2023;7(2):236–245. doi:10.1182/bloodadvances.2022007496
   PubMed Web of Science ®Google Scholar
• Sperling AS, Guerra VA, Kennedy JA, et al. Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms. Blood. 2022; 140(16):1753–1763. doi:10.1182/blood.20210
   PubMed Web of Science ®Google Scholar